BiomX Inc. Q2 2025 Earnings Recap

PHGE Q2 2025 August 13, 2025

BiomX delivered noteworthy advancements in its clinical pipeline during Q2 2025, highlighted by the successful initiation of its Phase IIb trial for BX004 and positive data for BX211, positioning the company well for future growth.

Earnings Per Share Beat

$0.19 vs $-0.33 est.

+157.6% surprise

Market Reaction

1-Day +1.38%

5-Day +4.77%

30-Day -1.91%

Key Takeaways

Initiated patient dosing in Phase IIb trial for BX004, targeting cystic fibrosis, with top-line results expected in Q1 2026.
Published significant Phase Ib/IIa results for BX004, demonstrating a 500-fold improvement in bacterial reduction without resistance emergence.
BX211 received strong endorsements from key opinion leaders following positive Phase II results, emphasizing its potential in treating diabetic foot osteomyelitis.
Continued discussions are underway with the U.S. Defense Health Agency regarding BX211's registrational study and FDA feedback expected in H2 2025.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit PHGE on AllInvestView.

Next Q3 2025